abstract |
The present disclosure features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , W, X, Z, n, p, and Rings A and B are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present disclosure also features pharmaceutical compositions, method of treating, and kits thereof. |